Journal
Drug safety
Publication Date
10-1-2021
Volume
44
Issue
10
First Page
1109
Last Page
1119
Document Type
Open Access Publication
DOI
10.1007/s40264-021-01107-6
Rights and Permissions
Day, J.W., Mendell, J.R., Mercuri, E. et al. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Saf 44, 1109–1119 (2021). https://doi.org/10.1007/s40264-021-01107-6 This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Day, John W; Mendell, Jerry R; Mercuri, Eugenio; Finkel, Richard S; Strauss, Kevin A; Kleyn, Aaron; Tauscher-Wisniewski, Sitra; Tukov, Francis Fonyuy; Reyna, Sandra P; and Chand, Deepa H, "Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy." Drug safety. 44, 10. 1109 - 1119. (2021).
https://digitalcommons.wustl.edu/oa_4/795
